Trabucchi / Paoletti / Canal Biochemical and Neurophysiological Correlation of Centrally Acting Drugs

Second International Pharmacological Meeting
1. Auflage 2013
ISBN: 978-1-4831-8538-5
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 296 Seiten, Web PDF

Section on Pharmacology of the International Union of Physiological Sciences (SEPHAR), Proceedings of the Second International Pharmacological Meeting, August 20-23, 1963, Volume 2: Biochemical and Neurophysiological Correlation of Centrally Acting Drugs focuses on the composition, reactions, and applications of centrally acting drugs. The selection first offers information on the physiology of striopallidum in relation to extrapyramidal function and disorders and actions of dopa and dopamine in relation to function of the central nervous system. Discussions focus on correlation of behavioral and clinical states with metabolism of dopamine, functions of dopamine in the brain, and the central pharmacology of dopamine. The text then examines the role of brain dopamine (3-hydroxytyramine) in Parkinsonism, including behavior of dopamine in the extrapyramidal centers in patients with Parkinson's disease; brain dopamine and the extrapyramidal symptomatology of Parkinson's disease; and parallelism between Parkinson's disease and the Parkinson-like state induced by reserpine in man. The publication ponders on pharmacological studies on tremorine and metabolism of tremorine. The manuscript also takes a look at the contribution on the pathophysiology of intentional tremor; failure of Antiparkinson drugs to antagonize hypothermia in tremorine-treated rats; and significance of dopamine in psychomotor stimulant action. The selection is a dependable source of data for readers interested in centrally acting drugs.

Autoren/Hrsg.

Trabucchi, E.

Paoletti, R.

Canal, N.

Inhaltsverzeichnis

1;Front Cover;1
2;Biochemical and Neurophysiological Correlation of Centrally Acting Drugs;4
3;Copyright Page;5
4;Table of Contents;6
5;LIST OF AUTHORS;8
6;PART 1: DRUGS INTERFERING WITH THE EXTRAPYRAMIDAL SYSTEM;10
6.1;CHAPTER 1. PHYSIOLOGY OF THE STRIOPALLIDUM IN RELATION TO EXTRAPYRAMIDAL FUNCTION AND DISORDERS;12
6.1.1;ACKNOWLEDGEMENT;32
6.1.2;REFERENCES;32
6.2;CHAPTER 2. ACTIONS OF DOPA AND DOPAMINE IN RELATION TO FUNCTION OF THE CENTRAL NERVOUS SYSTEM;44
6.2.1;A. INTRODUCTION;44
6.2.2;B. CENTRAL PHARMACOLOGY OF DOPAMINE;45
6.2.3;C. CORRELATION OF BEHAVIOURAL AND CLINICAL STATES WITH METABOLISM OF DOPAMINE;52
6.2.4;D. FUNCTIONS OF DOPAMINE IN THE BRAIN;55
6.2.5;ACKNOWLEDGEMENT;57
6.2.6;REFERENCES;57
6.3;CHAPTER 3. DOPAMINE IN THE CENTRAL NERVOUS SYSTEM;60
6.4;CHAPTER 4. THE ROLE OF BRAIN DOPAMINE (3-HYDROXYTYRAMINE) IN PARKINSONISM;66
6.4.1;BEHAVIOUR OF DOPAMINE IN THE EXTRAPYRAMIDAL CENTRES IN PATIENTS WITH PARKINSON'S DISEASE;66
6.4.2;BRAIN DOPAMINE AND THE EXTRAPYRAMIDAL SYMPTOMATOLOGY OF PARKINSON'S DISEASE;67
6.4.3;SPECIFICITY AND THE SITE OF ACTION OF L-DOPA IN PARKINSON'S DISEASE;68
6.4.4;PARALLELISM BETWEEN PARKINSON'S DISEASE AND THE PARKINSON-LIKE STATE INDUCED BY RESERPINE IN MAN;70
6.4.5;PHARMACOLOGICAL DIFFERENCES BETWEEN THE RESERPINE-INDUCED STATE AND THAT OF PARKINSON'S DISEASE IN THE PERIPHERY;72
6.4.6;DOES THERE EXIST AN ABNORMALITY OF THE OVER-ALL METABOLISM OF DOPAMINE IN PARKINSON'S DISEASE?;73
6.4.7;WHAT MAKES THE DOPAMINE IN THE EXTRAPYRAMIDAL CENTRES DISAPPEAR IN PARKINSON'S DISEASE? HYPOTHETICAL SUGGESTIONS;73
6.4.8;NOTE ADDED IN PROOF;77
6.5;CHAPTER 5. PHARMACOLOGICAL STUDIES ON TREMORINE;78
6.6;CHAPTER 6. THE METABOLISM OF TREMORINE;84
6.6.1;PHARMACOLOGY OF OXOTREMORINE;85
6.6.2;OTHER METABOLITES OF TREMORINE;85
6.6.3;CONCLUSIONS;88
6.6.4;REFERENCES;88
6.7;CHAPTER 7. CONTRIBUTION ON THE PATHOPHYSIOLOGY OF INTENTIONAL TREMOR;90
6.7.1;ACKNOWLEDGMENT;97
6.8;CHAPTER 8. MÉDICAMENTS AGISSANT SUR LA SYMPTOMATOLOGIE EXTRA-PYRAMIDALE DES NEUROLEPTIQUES;102
6.9;CHAPTER 9. FAILURE OF ANTIPARKINSON DRUGS TO ANTAGONIZE HYPOTHERMIA IN TREMORINE-TREATED RATS;114
6.10;CHAPTER 10. DE L'ANTAGONISME VIS-A-VIS DE DIFFÉRENTS EFFETS DE LA TRÉMORINE CHEZ LA SOURIS;118
6.10.1;CONCLUSIONS;123
6.11;CHAPTER 11. SIGNIFICANCE OF DOPAMINE IN PSYCHOMOTOR STIMULANT ACTION;124
6.11.1;INTRODUCTION;124
6.11.2;NEUROCHEMISTRY AND PATHOLOGY;124
6.11.3;STRUCTURE–ACTIVITY RELATIONS;126
6.11.4;DIRECT AND INDIRECT ACTION;128
6.11.5;DEPLETING AND RELOADING CATECHOLAMINE STORES;130
6.11.6;SELECTIVE DEPLETION OF NORADRENALINE STORES;133
6.11.7;CONCLUSION;133
6.11.8;ACKNOWLEDGEMENTS;134
6.11.9;REFERENCES;134
6.11.10;DISCUSSION TO PART I;136
7;PART 2: DRUGS INTERFERING WITH THERMOREGULATION;142
7.1;CHAPTER 12. THE PHYSIOLOGY AND PHARMACOLOGY OF TEMPERATURE REGULATION WITH PARTICULAR REFERENCE TO THE CHEMICAL MEDIATORS;144
7.2;CHAPTER 13. THE PHYSIOLOGY OF THERMOREGULATION;154
7.2.1;ACKNOWLEDGEMENT;161
7.3;CHAPTER 14. AN ANALYSIS OF HYPERTHERMIA INDUCED BY 5-HTP;164
7.3.1;METHODS;166
7.3.2;RESULTS AND DISCUSSION;169
7.3.3;SUMMARY;171
7.3.4;REFERENCES;171
7.4;CHAPTER 15. DROGUES HYPOTHERMISANTES;174
7.4.1;GÉNÉRALITÉS;174
7.4.2;I. PHYSIOLOGIE;175
7.4.3;II. LES DROGUES HYPOTHERMISANTES;187
7.4.4;I. ACTION HYPOTHERMISANTE POUR LAQUELLE UN MÉCANISME MÉTABOLIQUE PEUT ÊTRE INVOQUÉ ET INTÉGRÉ AUX DIFFÉRENTS NIVEAUX D'ORGANISATION;190
7.4.5;II. ACTION HYPOTHERMISANTE POUR LAQUELLE SEUL UN MÉCANISME NERVEUX PÉRIPHÉRIQUE PEUT ÊTRE ACTUELLEMENT INVOQUÉ;203
7.5;CHAPTER 16. ACTION DES INHIBITEURS DE LA L-DOPA/5 HTP DÉCARBOXYLASE EN HYPOTHERMIE;212
7.6;CHAPTER 17. PHARMACOLOGICAL STUDIES ON THE EFFECT CAUSED BY PYROGEN ON RABBITS;220
7.7;CHAPTER 18. CATECHOLAMINE-INDUCED ENDOTOXIN-LIKE FEVER;228
7.8;CHAPTER 19. THE ROLE OF AUTONOMIC NERVOUS FUNCTION IN MAMMALIAN THERMOREGULATION;234
7.9;CHAPTER 20. METABOLIC IMPLICATIONS OF COLD ADAPTATION;248
7.9.1;ACKNOWLEDGEMENT;255
7.9.2;REFERENCES;255
7.10;CHAPTER 21. ANTAGONISTES DE L'ACTION HYPERTHERMISANTE DU LYSERGAMIDE CHEZ LE LAPIN;258
7.10.1;MÉTHODE;259
7.10.2;RÉSULTATS;260
7.10.3;DISCUSSION;266
7.10.4;REMERCIEMENT;269
7.10.5;RÉSUMÉ;269
7.10.6;SUMMARY;269
7.11;CHAPTER 22. NEURO-STIMULANTS HALLUCINOGÈNES ET NON HALLUCINOGÈNES: CONFRONTATION EXPÉRIMENTALE DE LEURS EFFETS SUR LES TEMPÉRATURES CENTRALE ET PÉRIPHÉRIQUE;272
7.11.1;COMPARAISON AVEC LA MÉTHAMPHÉTAMINE;282
7.11.2;COMPARAISON AVEC LES PRÉCURSEURS DES AMINES BIOGÈNES;283
7.11.3;CONCLUSION;286
8;DISCUSSION TO PART II;288
9;INDEX;290